Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea

• Published in: Journal of clinical neurology (Seoul, Korea) Vol. 21; no. 2; pp. 131 - 136
• Main Authors: Kim, Su-Hyun, Min, Ju-Hong, Kim, Sung-Min, Lee, Eun-Jae, Lim, Young-Min, Shin, Ha Young, Kwon, Young Nam, Sohn, Eunhee, Kim, Sooyoung, Park, Min Su, Nam, Tai-Seung, Yoon, Byeol-A, Kim, Jong Kuk, Shin, Kyong Jin, Kim, Yoo Hwan, Seok, Jin Myoung, Bong, Jeong Bin, Kim, Sohyeon, Seok, Hung Youl, Oh, Sun-Young, Kwon, Ohyun, Kim, Sunyoung, Lee, Sukyoon, Kim, Nam-Hee, Cho, Eun Bin, Kang, Sa-Yoon, Oh, Seong-il, Bae, Jong Seok, Ahn, Suk-Won, Kim, Ki Hoon, Kang, You-Ri, Ju, Woohee, Choo, Seung Ho, Chung, Yeon Hak, Hyun, Jae-Won, Kim, Ho Jin
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Neurological Association 01.03.2025; 대한신경과학회
• Subjects: Original; 신경과학; satralizumab; eculizumab; inebilizumab; rituximab; neuromyelitis optica
• ISSN: 1738-6586; 2005-5013
• DOI: 10.3988/jcn.2024.0485

Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15-87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse. Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.